Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis subsp. lactis BL-11
- Development stage
- Unknown
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis BL-11 is a specific probiotic strain of the species Bifidobacterium animalis subsp. lactis, used as a live biotherapeutic product and dietary supplement. It is a non-pathogenic, beneficial bacterium that colonizes the human gut and produces lactic and acetic acid[2][5]. Mechanistically, it supports intestinal health by modulating the gut microbiota composition—promoting beneficial bacteria (such as other Bifidobacteria and Lactobacilli) while reducing strains associated with obesity and inflammation[3]. Clinical studies have shown that daily administration of this strain can significantly promote height growth in children with short stature or Prader-Willi syndrome over 12 weeks[1][3][4]. The proposed benefits are attributed to improved nutrient absorption, metabolic balance, enhanced bone growth signaling via gut-microbiome interactions, and overall support for healthy development[1][6].
- Brand names
- BL-11BL11BL 11
- Other names
- bifidobacterium animalis subsp. lactis BL-11Bifidobacterium lactis BL-11B. lactis BL-11
Beyond the preview
Go deeper on bifidobacterium animalis subsp. lactis BL-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis subsp. lactis BL-11.